Aduro BioTech Inc (NASDAQ:ADRO) has received an average rating of “Hold” from the nine analysts that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $14.40.
Several equities analysts have recently issued reports on the stock. HC Wainwright set a $8.00 price target on shares of Aduro BioTech and gave the company a “buy” rating in a research note on Tuesday, October 2nd. ValuEngine downgraded shares of Aduro BioTech from a “sell” rating to a “strong sell” rating in a research note on Tuesday, July 24th. BidaskClub raised shares of Aduro BioTech from a “strong sell” rating to a “sell” rating in a research note on Friday, August 31st. William Blair reaffirmed a “buy” rating on shares of Aduro BioTech in a research note on Wednesday, October 3rd. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $30.00 price target on shares of Aduro BioTech in a research note on Thursday, August 2nd.
In related news, insider Stephen T. Isaacs sold 62,572 shares of Aduro BioTech stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $7.91, for a total transaction of $494,944.52. Following the completion of the transaction, the insider now owns 221,331 shares of the company’s stock, valued at $1,750,728.21. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Blaine Templeman sold 10,262 shares of Aduro BioTech stock in a transaction on Monday, September 24th. The stock was sold at an average price of $5.81, for a total transaction of $59,622.22. Following the transaction, the insider now directly owns 131,119 shares of the company’s stock, valued at approximately $761,801.39. The disclosure for this sale can be found here. Insiders have sold 123,614 shares of company stock valued at $892,283 in the last three months. 5.00% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Capital Fund Management S.A. bought a new position in Aduro BioTech during the second quarter worth $130,000. Sofinnova Ventures Inc bought a new position in Aduro BioTech during the first quarter worth $155,000. Legal & General Group Plc raised its stake in Aduro BioTech by 105.3% during the first quarter. Legal & General Group Plc now owns 22,233 shares of the biotechnology company’s stock worth $206,000 after buying an additional 11,405 shares during the last quarter. MetLife Investment Advisors LLC raised its stake in Aduro BioTech by 70.6% during the second quarter. MetLife Investment Advisors LLC now owns 31,799 shares of the biotechnology company’s stock worth $223,000 after buying an additional 13,156 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in Aduro BioTech by 144.8% during the second quarter. Bank of America Corp DE now owns 37,141 shares of the biotechnology company’s stock worth $260,000 after buying an additional 21,967 shares during the last quarter. 49.00% of the stock is owned by institutional investors and hedge funds.
Aduro BioTech stock remained flat at $$6.08 during mid-day trading on Wednesday. 437,930 shares of the company’s stock were exchanged, compared to its average volume of 470,993. Aduro BioTech has a 1 year low of $5.10 and a 1 year high of $10.10. The firm has a market capitalization of $581.09 million, a price-to-earnings ratio of -4.28 and a beta of 2.22.
Aduro BioTech (NASDAQ:ADRO) last issued its earnings results on Wednesday, August 1st. The biotechnology company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.02. Aduro BioTech had a negative net margin of 574.11% and a negative return on equity of 44.97%. The firm had revenue of $2.64 million for the quarter, compared to analyst estimates of $3.74 million. Equities research analysts forecast that Aduro BioTech will post -1.25 earnings per share for the current year.
Aduro BioTech Company Profile
Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.
Recommended Story: Market Capitalization – What it Means for Investors
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.